DexCom, Inc.(DXCM)Earnings, Financials & Key RatiosDexCom, Inc. (DXCM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully reduced its debt-to-equity ratio to 0.45, the high PEG ratio of 3.20 and ongoing margin volatility suggest that investors should wait for more consistent top-line growth before increasing exposure.
DexCom, Inc. (DXCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
DexCom, Inc. (DXCM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.56vs $0.47+20.3% | $1.2Bvs $1.2B+1.5% |
| Q1 2026 | Feb 12, 2026 | $0.68vs $0.65+4.6% | $1.3Bvs $1.2B+0.9% |
| Q4 2025 | Oct 30, 2025 | $0.61vs $0.58+5.9% | $1.2Bvs $1.2B+2.2% |
| Q3 2025 | Jul 30, 2025 | $0.48vs $0.44+8.2% | $1.2Bvs $1.1B+2.9% |
Recent stock market news and headlines for DexCom, Inc. (DXCM)
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.
Key metrics vs top competitors for DexCom, Inc. (DXCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $73.57 | $28.39B | 35.20 | 15.6% | 17.94% | 34.5% | — | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — | |
| $161.55 | $11.34B | 46.42 | 30.73% | 10.44% | 21.38% | — | |
| $15.43 | $1.06B | -5.08 | 7.93% | -9.2% | -68.29% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — |
DexCom, Inc. (DXCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DexCom, Inc. (DXCM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Mar 2, 2026·SEC
Feb 26, 2026·SEC
Get notified when DXCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DexCom, Inc. (DXCM) stock FAQ — growth, dividends, profitability & financials explained
DexCom, Inc. (DXCM) reported $4.82B in revenue for fiscal year 2025.
DexCom, Inc. (DXCM) grew revenue by 15.6% over the past year. This is strong growth.
Yes, DexCom, Inc. (DXCM) is profitable, generating $930.4M in net income for fiscal year 2025 (17.9% net margin).
DexCom, Inc. (DXCM) has a return on equity (ROE) of 34.5%. This is excellent, indicating efficient use of shareholder capital.
DexCom, Inc. (DXCM) generated $1.43B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
